Search

Your search keyword '"Uharek, Lutz"' showing total 191 results
Start Over Author "Uharek, Lutz" Language english
191 results on '"Uharek, Lutz"'

1. Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation

Author

Schmidt, Volker, Niederwieser, Dietger, Schenk, Thomas, Behre, Gerhard, Klink, Anne, Pfrepper, Christian, Hinke, Axel, Beelen, Dietrich W., Junghanss, Christian, Uharek, Lutz, Krüger, William H., Hochhaus, Andreas, Sayer, Herbert G., and for the East German Study Group for Hematology and Oncology (OSHO)

Published
2018
Full Text
View/download PDF

5. Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions—A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group

Author

Schroeder, Thomas, Rachlis, Elena, Bug, Gesine, Stelljes, Matthias, Klein, Stefan, Steckel, Nina Kristin, Wolf, Dominik, Ringhoffer, Mark, Czibere, Akos, Nachtkamp, Kathrin, Dienst, Ariane, Kondakci, Mustafa, Stadler, Michael, Platzbecker, Uwe, Uharek, Lutz, Luft, Thomas, Fenk, Roland, Germing, Ulrich, Bornhäuser, Martin, Kröger, Nicolaus, Beelen, Dietrich W., Haas, Rainer, and Kobbe, Guido

Published
2015
Full Text
View/download PDF

8. Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor‐risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial

Author

Scheffold, Annika, Jebaraj, Billy Michael Chelliah, Jaramillo, Sonia, Tausch, Eugen, Steinbrecher, Daniela, Hahn, Michael, Böttcher, Sebastian, Ritgen, Matthias, Bunjes, Donald, Zeis, Matthias, Stadler, Michael, Uharek, Lutz, Scheid, Christoph, Hegenbart, Ute, Hallek, Michael, Kneba, Michael, Schmitz, Norbert, Döhner, Hartmut, Dreger, Peter, and Stilgenbauer, Stephan

Published
2017
Full Text
View/download PDF

10. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

Author

Dreger, Peter, Döhner, Hartmut, Ritgen, Matthias, Böttcher, Sebastian, Busch, Raymonde, Dietrich, Sascha, Bunjes, Donald, Cohen, Sandra, Schubert, Jörg, Hegenbart, Ute, Beelen, Dietrich, Zeis, Matthias, Stadler, Michael, Hasenkamp, Justin, Uharek, Lutz, Scheid, Christof, Humpe, Andreas, Zenz, Thorsten, Winkler, Dirk, Hallek, Michael, Kneba, Michael, Schmitz, Norbert, and Stilgenbauer, Stephan

Published
2010
Full Text
View/download PDF

11. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study

Author

Bethge, Wolfgang A., Lange, Thoralf, Meisner, Christoph, von Harsdorf, Stephanie, Bornhaeuser, Martin, Federmann, Birgit, Stadler, Michael, Uharek, Lutz, Stelljes, Matthias, Knop, Stefan, Wulf, Gerald, Trenschel, Rudolf, Vucinic, Vladan, Dittmann, Helmut, Faul, Christoph, Vogel, Wichard, Kanz, Lothar, and Bunjes, Donald

Published
2010
Full Text
View/download PDF

13. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Author

Kröger, Nicolaus, Holler, Ernst, Kobbe, Guido, Bornhäuser, Martin, Schwerdtfeger, Rainer, Baurmann, Herrad, Nagler, Arnon, Bethge, Wolfgang, Stelljes, Matthias, Uharek, Lutz, Wandt, Hannes, Burchert, Andreas, Corradini, Paolo, Schubert, Jörg, Kaufmann, Martin, Dreger, Peter, Wulf, Gerald G., Einsele, Hermann, Zabelina, Tatjana, Kvasnicka, Hans Michael, Thiele, Jürgen, Brand, Ronald, Zander, Axel R., Niederwieser, Dietger, and de Witte, Theo M.

Published
2009
Full Text
View/download PDF

16. MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease

Author

Heimesaat, Markus M., Nogai, Axel, Bereswill, Stefan, Plickert, Rita, Fischer, Andre, Loddenkemper, Christoph, Steinhoff, Ulrich, Tchaptchet, Sandrine, Thiel, Eckhard, Freudenberg, Marina A., Gobel, Ulf B., and Uharek, Lutz

Subjects
Graft versus host reaction -- Development and progression, Graft versus host reaction -- Models, Graft versus host reaction -- Research, Microbiota (Symbiotic organisms) -- Physiological aspects, Microbiota (Symbiotic organisms) -- Research, Membrane proteins -- Physiological aspects, Membrane proteins -- Research, Health
Published
2010

28. Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse

Author

Burmeister Thomas, Molkentin Mara, Meyer Claus, Lachmann Nils, Schwartz Stefan, Friedrichs Birte, Beyer Jörg, Blau Igor, Lohm Gunnar, Tietze-Bürger Carola, Marschalek Rolf, and Uharek Lutz

Subjects
Minimal residual disease, Haploidentical stem cell transplantation, MLL, KIR, Acute myeloid leukemia, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract This report describes the clinical courses of two acute myeloid leukemia patients. Both had MLL translocations, the first a t(10;11)(p11.2;q23) with MLL-AF10 and the second a t(11;19)(q23;p13.1) with MLL-ELL fusion. They achieved a clinical remission under conventional chemotherapy but relapsed shortly after end of therapy. Both had a history of invasive mycoses (one had possible pulmonary mycosis, one systemic candidiasis). Because no HLA-identical donor was available, a haploidentical transplantation was performed in both cases. Using a specially designed PCR method for the assessment of minimal residual disease (MRD), based on the quantitative detection of the individual chromosomal breakpoint in the MLL gene, both patients achieved complete and persistent molecular remission after transplantation. The immune reconstitution after transplantation is described in terms of total CD3+/CD4+, CD3+/CD8+, CD19+, and CD16+/CD56+ cell numbers over time. The KIR and HLA genotypes of donors and recipients are reported and the possibility of a KIR-mediated alloreactivity is discussed. This report illustrates that haploidentical transplantation may offer a chance of cure without chronic graft-versus-host disease in situations where no suitable HLA-identical donor is available even in a high-risk setting and shows the value of MRD monitoring in the pre- and posttransplant setting.

Published
2012
Full Text
View/download PDF

32. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial

Author

Dreger, Peter, Schnaiter, Andrea, Zenz, Thorsten, Böttcher, Sebastian, Rossi, Marianna, Paschka, Peter, Bühler, Andreas, Dietrich, Sascha, Busch, Raymonde, Ritgen, Matthias, Bunjes, Donald, Zeis, Matthias, Stadler, Michael, Uharek, Lutz, Scheid, Christof, Hegenbart, Ute, Hallek, Michael, Kneba, Michael, Schmitz, Norbert, Döhner, Hartmut, and Stilgenbauer, Stephan

Published
2013
Full Text
View/download PDF

34. Immunological Aspects of Candida and Aspergillus Systemic Fungal Infections

Author

Mueller-Loebnitz, Christoph, Ostermann, Helmut, Franzke, Anke, Loeffler, Juergen, Uharek, Lutz, Topp, Max, and Einsele, Hermann

Subjects
Article Subject
Abstract

Patients with allogeneic stem cell transplantation (SCT) have a high risk of invasive fungal infections (IFIs) even after neutrophil regeneration. Immunological aspects might play a very important role in the IFI development in these patients. Some data are available supporting the identification of high-risk patients with IFI for example patients receiving stem cells from TLR4 haplotype S4 positive donors. Key defense mechanisms against IFI include the activation of neutrophils, the phagocytosis of germinating conidia by dendritic cells, and the fight of the cells of the innate immunity such as monocytes and natural killer cells against germlings and hyphae. Furthermore, immunosuppressive drugs interact with immune effector cells influencing the specific fungal immune defense and antimycotic drugs might interact with immune response. Based on the current knowledge on immunological mechanism in Aspergillus fumigatus, the first approaches of an immunotherapy using human T cells are in development. This might be an option for the future of aspergillosis patients having a poor prognosis with conventional treatment.

Published
2013
Full Text
View/download PDF

35. Prospective evaluation of the Septi FAST multiplex real-time PCR assay for surveillance and diagnosis of infections in haematological patients after allogeneic stem cell transplantation compared to routine microbiological assays and an in-house real-time PCR method

Author

Elges, Sandra, Arnold, Renate, Liesenfeld, Oliver, Kofla, Grzegorz, Mikolajewska, Agata, Schwartz, Stefan, Uharek, Lutz, and Ruhnke, Markus

Subjects
DIAGNOSTIC use of polymerase chain reaction, POLYMERIZATION reactors, HEMATOLOGIC malignancies, GENETICS of staphylococcus aureus infections, GENETICS of bacterial diseases, GENETICS
Abstract

We prospectively evaluated a multiplex real-time PCR assay (SeptiFast, SF) in a cohort of patients undergoing allo- BMT in comparison to an in-house PCR method ( IH- PCR). Overall 847 blood samples (mean 8 samples/patient) from 104 patients with haematological malignancies were analysed. The majority of patients had acute leukaemia (62%) with a mean age of 52 years (54% female). Pathogens could be detected in 91 of 847 (11%) samples by SF compared to 38 of 205 (18.5%) samples by BC, and 57 of 847 (6.7%) samples by IH- PCR. Coagulase-negative staphylococci (n=41 in SF, n=29 in BC) were the most frequently detected bacteria followed by Escherichia coli (n=9 in SF, n=6 in BC). Candida albicans (n=17 in SF, n=0 in BC, n=24 in IH- PCR) was the most frequently detected fungal pathogen. SF gave positive results in 5% of samples during surveillance vs in 26% of samples during fever episodes. Overall, the majority of blood samples gave negative results in both PCR methods resulting in 93% overall agreement resulting in a negative predictive value of 0.96 (95% CI: 0.95-0.97), and a positive predictive value of 0.10 (95% CI: −0.01 to 0.21). SeptiFast appeared to be superior over BC and the IH- PCR method. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

36. 29 - Safety and Efficacy of Donor T Cells Engineered with Herpes Simplex Virus Thymidine-Kinase Suicide Gene (TK Cells) Given after T-Cell Depleted (TCD) Haploidentical Hematopoietic Transplantation (Haplo-HSCT): Results of a 14-Year Follow-Up in 45 Patients

Author

Ciceri, Fabio, Bonini, Chiara, Labopin, Myriam, Oliveira, Giacomo, Nagler, Arnon, Yannaki, Evangelia, Stanghellini, Maria Teresa Lupo, Bondanza, Attilio, Greco, Raffaella, Olavarria, Eduardo, Weissinger, Eva, Stadler, Michael, Bunjes, Donald, Niederwieser, Dietger, Uharek, Lutz, Bethge, Wolfgang, DiPersio, John, Pecora, Andrew L., Donato, Michele, Colombi, Scialini, Lambiase, Antonio, Bordignon, Claudio, and Mohty, Mohamad

Published
2017
Full Text
View/download PDF

37. Impact of Immune Reconstitution (IR) and Graft-Versus-Host Disease (GvHD) on Clinical Outcomes after Treatment with Donor T Cells Transduced to Express the Herpes Simplex Virus Thymidine-Kinase Suicide Gene (TK cells) in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)

Author

Ciceri, Fabio, Bonini, Chiara, Nagler, Arnon, Yannaki, Evangelia, Lupo Stanghellini, Maria Teresa, Bondanza, Attilio, Greco, Raffaella, Olovarria, Eduardo, Mischak-Weissinger, Eva M., Stadler, Michael, Bunjes, Donald w., Niederwieser, Dietger, Uharek, Lutz, Betghe, Wolfgang, DiPersio, John F, Donato, Michele L., Pecora, Andrew L., Colombi, Scialini, Lambiase, Antonio, and Bordignon, Claudio

Published
2016
Full Text
View/download PDF

39. Long Term Follow up of the AML97-Study for Patients with AML Older Than 60 Years: A Study of the East German Hematology and Oncology Study Group (OSHO)

Author

Kahl, Christoph, Krahl, Rainer, Al-Ali, Haifa Kathrin, Sayer, Herbert G., Schulze, Antje, Herold, Michael, Hänel, Mathias, Scholl, Sebastian, Hochhaus, Andreas, Uharek, Lutz, Maschmeyer, Georg, Hähling, Detlev, Junghanss, Christian, Peter, Norma, Kämpfe, Dietrich, Kettner, Erika, Heinicke, Thomas, Fischer, Thomas, Kreibich, Ute, Wolf, Hans-Heinrich, and Niederwieser, Dietger

Published
2014
Full Text
View/download PDF

40. Haploidentical Second Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Acute Leukemia Relapse after First Allo-HSCT: A Retrospective Registry Analysis of 60 Patients on Behalf of the German Cooperative Transplant Group

Author

Christopeit, Maximilian, Tischer, Johanna, Bornhäuser, Martin, Uharek, Lutz, Pfrepper, Christian, Behre, Gerhard, Niederwieser, Dietger, Kröger, Nicolaus, Rösler, Wolf, Klein, Stefan A., Beelen, Dietrich, Hausmann, Andreas, Bethge, Wolfgang, and Schmid, Christoph

Published
2014
Full Text
View/download PDF

41. Infusion of Donor Lymphocytes Genetically Engineered to Express the Herpes Simplex Virus Thymidine Kinase (HSV-TK) Suicide Gene after Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Preliminary Efficacy Data from the Randomized TK008 Study

Author

Bonini, Chiara, Ciceri, Fabio, Nagler, Arnon, Yannaki, Evangelia, Lupo Stanghellini, Maria Teresa, Oliveira, Giacomo, Bondanza, Attilio, Vago, Luca, Greco, Raffaella, Peccatori, Jacopo, Olovarria, Eduardo, Mischak-Weissinger, Eva M., Stadler, Michael, Bunjes, Donald, Niederwieser, Dietger, Uharek, Lutz, Bethge, Wolfgang A., DiPersio, John F., Donato, Michele L, Pecora, Andrew L, Colombi, Scialini, Antonio, Lambiase, and Bordignon, Claudio

Published
2014
Full Text
View/download PDF

43. Tracking in vivo dynamics of NK cells transferred in patients undergoing stem cell transplantation.

Author

Killig, Monica, Friedrichs, Birte, Meisig, Johannes, Gentilini, Chiara, Blüthgen, Nils, Loddenkemper, Christoph, Labopin, Myriam, Basara, Nadezda, Pfrepper, Christian, Niederwieser, Dietger W., Uharek, Lutz, and Romagnani, Chiara

Abstract

Haploidentical stem cell transplantation (haploSCT) offers an alternative treatment option for advanced leukemia patients lacking a HLA-compatible donor. Transfer of NK cells represents a promising therapeutic option in combination with SCT, as NK cells can promote graft versus leukemia with low risk of GVH disease. In this study, we show results from a phase I/II trial in which 24 acute myeloid leukemia patients underwent haploSCT in combination with early transfer of unmodified NK cells and observed a promising 2-year overall survival rate of 37%. By performing immunomonitoring and subsequent principal component analysis, we tracked donor NK-cell dynamics in the patients and distinguished between NK cells reconstituting from CD34+ precursors, giving rise over time to a continuum of multiple differentiation stages, and adoptively transferred NK cells. Transferred NK cells displayed a mature phenotype and proliferated in vivo during the early days after haploSCT even in the absence of exogenous IL-2 administration. Moreover, we identified the NK-cell phenotype associated with in vivo expansion. Thus, our study indicates a promising path for adoptive transfer of unmodified NK cells in the treatment of high-risk acute myeloid leukemia. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

44. Randomised, double-blind, placebo-controlled trial of oral budesonide for prophylaxis of acute intestinal graft-versus-host disease after allogeneic stem cell transplantation (PROGAST).

Author

Schmelz, Renate, Bornhäuser, Martin, Schetelig, Johannes, Kiani, Alexander, Platzbecker, Uwe, Schwanebeck, Uta, Grählert, Xina, Uharek, Lutz, Aust, Daniela, Baretton, Gustavo, Schwerdtfeger, Rainer, Hampe, Jochen, Greinwald, Roland, Mueller, Ralph, Ehninger, Gerhard, and Miehlke, Stephan

Abstract

Background: Gastrointestinal graft–versus-host disease (GvHD) is a potentially life-threatening complication after allogeneic stem cell transplantation (SCT). Since therapeutic options are still limited, a prophylactic approach seems to be warranted. Methods: In this randomised, double-blind-phase III trial, we evaluated the efficacy of budesonide in the prophylaxis of acute intestinal GvHD after SCT. The trial was registered at https://clinicaltrials.gov, number NCT00180089. Patients were randomly assigned to receive either 3 mg capsule three times daily oral budesonide or placebo. Budesonide was applied as a capsule with pH-modified release in the terminal ileum. Study medication was administered through day 56, follow-up continued until 12 months after transplantation. If any clinical signs of acute intestinal GvHD appeared, an ileocolonoscopy with biopsy specimens was performed. Results: The crude incidence of histological or clinical stage 3–4 acute intestinal GvHD until day 100 observed in 91 (n =48 budesonide, n =43 placebo) evaluable patients was 12.5% (95% CI 3-22%) under treatment with budesonide and 14% (95% CI 4-25%) under placebo (p = 0.888). Histologic and clinical stage 3–4 intestinal GvHD after 12 months occurred in 17% (95% CI 6-28%) of patients in the budesonide group and 19% (CI 7-32%) in the placebo group (p = 0.853). Although budesonide was tolerated well, we observed a trend towards a higher rate of infectious complications in the study group (47.9% versus 30.2%, p = 0.085). The cumulative incidences at 12 months of intestinal GvHD stage >2 with death as a competing event (budesonide 20.8% vs. placebo 32.6%, p = 0.250) and the cumulative incidence of relapse (budesonide 20.8% vs. placebo 16.3%, p = 0.547) and non-relapse mortality (budesonide 28% (95% CI 15-41%) vs. placebo 30% (95% CI 15-44%), showed no significant difference within the two groups (p = 0.911). The trial closed after 94 patients were enrolled because of slow accrual. Within the limits of the final sample size, we were unable to show any benefit for the addition of budesonide to standard GvHD prophylaxis. Conclusions: Budesonide did not decrease the occurrence of intestinal GvHD in this trial. These results imply most likely that prophylactic administration of budenoside with pH-modified release in the terminal ileum is not effective. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

45. Genetically Modified T Cells for the Treatment of Malignant Disease.

Author

Wieczorek, Agnieszka and Uharek, Lutz

Abstract

SummaryThe broaden application of adoptive T-cell transfer has been constrained by the technical abilities to isolate and expand antigen-specific T cells potent to selectively kill tumor cells. With the recent progress in the design and manufacturing of cellular products, T cells used in the treatment of malignant diseases may be regarded as anticancer biopharmaceuticals. Genetical manipulation of T cells has given T cells desired specificity but also enable to tailor their activation and proliferation potential. Here, we summarize the recent developments in genetic engineering of T-cell-based biopharmaceuticals, covering criteria for their clinical application in regard to safety and efficacy. © 2014 S. Karger GmbH, Freiburg [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

46. Azacitidine and Donor Lymphocyte Infusions As Treatment For Relapse After Allogeneic Stem Cell Transplantation - a Retrospective Multicenter Analysis In 115 Patients On Behalf Of The German Cooperative Transplant Study Group

Author

Schroeder, Thomas, Rachlis, Elena, Bug, Gesine, Stelljes, Matthias, Klein, Stefan A., Wolf, Dominik, Ringhoffer, Mark, Czibere, Akos G., Nachtkamp, Kathrin, Dienst, Ariane, Kondakci, Mustafa, Stadler, Michael, Platzbecker, Uwe, Uharek, Lutz, Luft, Thomas, Fenk, Roland, Germing, Ulrich, Bornhäuser, Martin, Kröger, Nicolaus, Haas, Rainer, and Kobbe, Guido

Published
2013
Full Text
View/download PDF

48. Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change.

Author

Christopeit, Maximilian, Kuss, Oliver, Finke, Jurgen, Bacher, Ulrike, Beelen, Dietrich Wilhelm, Bornhäuser, Martin, Schwerdtfeger, Rainer, Bethge, Wolfgang Andreas, Basara, Nadezda, Gramatzki, Martin, Tischer, Johanna, Kolb, Hans-Jochem, Uharek, Lutz, Meyer, Ralf G., Bunjes, Donald, Scheid, Christof, Martin, Hans, Niederwieser, Dietger, Kröger, Nicolaus, and Bertz, Hartmut

Published
2013
Full Text
View/download PDF

49. Utilization of TREC and KREC quantification for the monitoring of early T- and B-cell neogenesis in adult patients after allogeneic hematopoietic stem cell transplantation.

Author

Mensen, Angela, Ochs, Christoph, Stroux, Andrea, Wittenbecher, Friedrich, Szyska, Martin, Imberti, Luisa, Fillatreau, Simon, Uharek, Lutz, Arnold, Renate, Dörken, Bernd, Thiel, Andreas, Scheibenbogen, Carmen, and Il-Kang Na

Subjects
T cell receptors, B cells, HEMATOPOIETIC stem cell transplantation, LYMPHOCYTES, LEUKEMIA treatment, BONE marrow, FLOW cytometry
Abstract

Background: After hematopoietic stem cell transplantation (HSCT) T- and B-cell reconstitution from primary lymphoid organs are a prerequisite for an effective early lymphocyte reconstitution and a long-term survival for adult patients suffering from acute leukemia. Here, we asked whether quantification of T cell receptor excision circle, (TREC) and kappa-deleting recombination excision circle (KREC) before and within six month after allogeneic HSCT could be used to measure the thymic and bone marrow outputs in such patients. Methods: We used a duplex real time PCR assay to quantify the absolute copy counts of TREC and KREC, and correlated the data with absolute cell counts of CD3+CD4+ T-cell and CD19+ B-cell subsets determined by flow cytometry, respectively. Results: By comparing two recently proposed naïve T cell subsets, CD31+ naive and CD31- naive T cells, we found a better correlation for the CD31+ subset with TREC level post alloHSCT, in line with the assumption that it contained T cells recently derived from the thymus, indicating that TREC levels reflected real thymic de novo production. Transitional as well as naïve B cells highly correlated with KREC levels, which suggested an association of KREC levels with ongoing bone marrow B cell output. CD45RO+ memory T cells and CD27+ memory B cells were significantly less correlated with TREC and KREC recovery, respectively. Conclusion: We conclude that simultaneous TREC/ KREC quantification is as a suitable and practicable method to monitor thymic and bone marrow output post alloHSCT in adult patients diagnosed with acute leukemia. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

50. SF3B1, NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial

Author

Dreger, Peter, Schnaiter, Andrea, Rossi, Marianna, Paschka, Peter, Bühler, Andreas, Zenz, Thorsten, Dietrich, Sascha, Böttcher, Sebastian, Bunjes, Donald, Stadler, Michael, Uharek, Lutz, Scheid, Christof, Hegenbart, Ute, Hallek, Michael, Kneba, Michael, Schmitz, Norbert, Döhner, Hartmut, and Stilgenbauer, Stephan

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results